with the latest trend of moving research outside Europe,
Nycomed-Amersham, a leading British drugs company is setting
up joint ventures in China and Brazil for conducting research
into genetic modification. The move will not only help
the company save money, but will also help it sidestep
protests in the UK. British drugs companies have also
been deterred from investing at home because of the growing
protest movements against GM research and animal testing.
to Sir William Castell, chief executive, the shifting
of genomic research to China would be significantly cheaper
than doing it in Europe or the US. This is brought about
by the huge differential in salary structures. It is envisaged
that the g roup could save $50m a year by employing 1,000
PhD-level researchers in China instead of Europe.
Nycomed-Amersham, which developed the
machines used to sequence the human genome, is considering involvement in a number of projects that would see it
take stakes in decoding the genomes of pigs, rice, citrus fruits and rainforest species.